Professional development Vacancies

Regarding amendments to the instructions for medical use of medicinal products containing ibrutinib (ibrutinib)

16.09.2021 1221 review

In view of the report of the Pharmacovigilance Risk Assessment Committee (PRAC) based on the analysis of Periodic Safety Update Reports (PSURs) for medicinal products containing ibrutinib, the Committee for Medicinal Products for Human Use (CHMP) made the following conclusions:

In view of the available data on hepatic adverse events (cases of hepatitis B reactivation and cases of hepatitis E, which may be chronic, as well as hepatic failure, including fatal events) obtained from spontaneous reports, including in some cases a close temporal relationship and positive de-challenge/re-challenge tests, the PRAC considers that a causal relationship between the use of medicinal products containing ibrutinib and hepatic events is at least possible.

PRAC concluded that registration certificate holders of medicinal products containing ibrutinib should make appropriate changes to the instructions for medical use in order to add recommendations on assessing liver function and viral hepatitis status before starting treatment with ibrutinib and periodic monitoring of changes in liver function parameters during treatment and, as clinically indicated, to perform viral load testing and serological testing for infectious hepatitis.

In view of the available data on ocular bleeding, including a large number of reports of events related to ocular hemorrhagic disorders (435 cases in total), of which 32 cases had a positive de-challenge, including 2 cases with a positive re-challenge (of which 1 case of intraocular hemorrhage that resulted in loss of vision), the imbalance in clinical trial data, and the plausible mechanism of action, since ibrutinib is known to be associated with bleeding and bleeding is an important identified risk for ibrutinib, the PRAC considers the causal relationship between the use of medicinal products containing ibrutinib and the occurrence of ocular bleeding to be established. In addition, since loss of vision occurred in some of these cases (in at least 20 cases, including one case with re-challenge), it is proposed to add this information to the instructions for medical use as well. The PRAC concluded that the holders of registration certificates for medicinal products containing ibrutinib should make the appropriate changes to the instructions for medical use.

CHMP agrees with the scientific conclusions drawn by PRAC.

Based on the scientific conclusions on ibrutinib, the CHMP is of the opinion that the benefit-risk balance of medicinal products containing ibrutinib remains unchanged, taking into account the proposed amendments to the instructions for medical use.

The CHMP recommends that registration certificate holders make changes to the registration materials.

Перелік лікарських засобів, що містять ібрутиніб (ibrutinib) і дозволені до медичного застосування в Україні (за даними Державного реєстру лікарських засобів станом на 01.09.2021)

To analyze the published information, the applicant must use the original text available at the linkhttps://www.ema.europa.eu/en/documents/scientific-conclusion/imbruvica-h-c-psusa-00010301-202011-epar-scientific-conclusions-grounds-variation-terms-marketing_en.pdf